Cargando…
A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models
One-third of diffuse large B-cell lymphoma patients are refractory to initial treatment or relapse after rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy. In these patients, CXCR4 overexpression (CXCR4(+)) associates with lower overall and disease-free survival....
Autores principales: | Falgàs, Aïda, Pallarès, Victor, Unzueta, Ugutz, Céspedes, María Virtudes, Arroyo-Solera, Irene, Moreno, María José, Sierra, Jorge, Gallardo, Alberto, Mangues, María Antonia, Vázquez, Esther, Villaverde, Antonio, Mangues, Ramon, Casanova, Isolda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049335/ https://www.ncbi.nlm.nih.gov/pubmed/31248974 http://dx.doi.org/10.3324/haematol.2018.211490 |
Ejemplares similares
-
Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4(+) Diffuse Large B-Cell Lymphoma Cells
por: Falgàs, Aïda, et al.
Publicado: (2021) -
Intracellular CXCR4(+) cell targeting with T22-empowered protein-only nanoparticles
por: Unzueta, Ugutz, et al.
Publicado: (2012) -
Efficient bioactive oligonucleotide‐protein conjugation for cell‐targeted cancer therapy
por: Aviñó, Anna, et al.
Publicado: (2019) -
Selective delivery of T22-PE24-H6 to CXCR4(+) diffuse large B-cell lymphoma cells leads to wide therapeutic index in a disseminated mouse model
por: Falgàs, Aïda, et al.
Publicado: (2020) -
An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination
por: Pallarès, Victor, et al.
Publicado: (2020)